Bridger Aerospace Announces Schedule for its First Quarter 2024 Earnings Release and Conference Call
May 07, 2024 08:03 ET
|
Bridger Aerospace Group Holdings, Inc.
BELGRADE, Mont., May 07, 2024 (GLOBE NEWSWIRE) -- Bridger Aerospace Group Holdings, Inc. (“Bridger” or “Bridger Aerospace”), (NASDAQ: BAER, BAERW), one of the nation’s largest aerial firefighting...
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
May 07, 2024 08:01 ET
|
Ardelyx, Inc.
WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
Zscaler Joins Forces with Google to Offer Unparalleled Zero Trust Data and Threat Protection
May 07, 2024 08:01 ET
|
Zscaler, Inc.
SAN JOSE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Zscaler, Inc. (NASDAQ: ZS), the leader in cloud security, has collaborated with Google on a joint zero trust architecture with Chrome Enterprise....
Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
May 07, 2024 08:01 ET
|
Mainz BioMed NV
Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
Great Lakes Reports First Quarter 2024 Results
May 07, 2024 08:00 ET
|
Great Lakes Dredge & Dock Corporation
First quarter net income of $21.0 millionFirst quarter adjusted EBITDA of $42.9 millionDredging backlog of $879.4 million at March 31, 2024 HOUSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Great Lakes...
Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights
May 07, 2024 08:00 ET
|
Nuvectis Pharma, Inc.
Encouraging preliminary data announced from the NXP800 Phase 1b study in platinum resistant, ARID1a-mutated ovarian cancer, a program granted Fast Track Designation by the US FDAData presented at the...
Windtree Therapeutics Regains Compliance with Nasdaq
May 07, 2024 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage...
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases
May 07, 2024 08:00 ET
|
Eterna Therapeutics
Eterna Therapeutics to Present at ASGCT on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M Locus
May 07, 2024 08:00 ET
|
Eterna Therapeutics
Eterna Therapeutics to present a poster at ASGCT on the Development of a mRNA-Engineered iPSC Line, via Targeted Insertion of HLA-E at the B2M Locus
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
May 07, 2024 08:00 ET
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update Announced positive feedback from both FDA and EMA on the regulatory path for the Phase 3...